Oct 03, 2022
RNS Number : 5404B MaxCyte, Inc. 03 October 2022   MaxCyte, Inc.   (" MaxCyte " or the "Company")   TOTAL VOTING RIGHTS AND BLOCK LISTING RETURN     Total Voting Rights Date: 3 October 2022 :   MaxCyte ( Nasdaq: MXCT; LSE: MXCT),   a leading commercial cell   -   engineering company focused on
Sep 28, 2022
RNS Number : 0021B MaxCyte, Inc. 28 September 2022                                                                                                                                                                           MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to
Sep 21, 2022
RNS Number : 1410A MaxCyte, Inc. 21 September 2022       MaxCyte Debuts New State-of-the-Art Headquarters in Maryland's I-270 Biotech Corridor    Expanded facilities illustrate MaxCyte's commitment to Montgomery County and the state of Maryland , building the life sciences community, and propelling
Sep 08, 2022
RNS Number : 6658Y MaxCyte, Inc. 08 September 2022   MaxCyte to Participate in Morgan Stanley 20 th Annual Global Healthcare Conference Rockville, MD , September 8, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling
Sep 01, 2022
RNS Number : 0087Y MaxCyte, Inc. 01 September 2022     MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights   Gaithersburg, Maryland - 1 September 2022 :       MaxCyte (LSE: MXCT),   a leading commercial cell - engineering company focused on providing enabling platform technologies to
Aug 11, 2022
RNS Number : 6259V MaxCyte, Inc. 11 August 2022           MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2022     ROCKVILLE, MD , August 11, 2022  -  MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a   leading commercial cell-engineering company focused on providing
Aug 11, 2022
RNS Number : 6262V MaxCyte, Inc. 11 August 2022           MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results   45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022   Raises 2022 Core Revenue Growth Guidance to Approximately 30%   ROCKVILLE, MD , August 11, 2022
Displaying 1 - 10 of 60